Silk Road Medical Inc. (SILK) Misses Q3 EPS by 10c

Silk Road Medical Inc. (NASDAQ: SILK) reported Q3 EPS of ($0.40), $0.10 worse than the analyst estimate of ($0.30). Revenue for the quarter came in at $24.7 million versus the consensus estimate of $26.23 million.

GUIDANCE:

Based on unforeseen impacts from the COVID-19 delta variant, Silk Road Medical now projects revenue for the full year 2021 to range from $99 million to $102 million, which represents 32% to 36% growth over the company’s prior year revenue.

For earnings history and earnings-related data on Silk Road Medical Inc. (SILK) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c
• Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c